Literature DB >> 3018955

An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity--a mechanism for thrombosis.

J M Freyssinet, M L Wiesel, J Gauchy, B Boneu, J P Cazenave.   

Abstract

An anticoagulant activity was isolated from the plasma of a patient with a strong lupus-like anticoagulant using gel filtration by high performance liquid chromatography. IgM were detected in this anticoagulant fraction which exhibited specificity towards 50% phosphatidylcholine - 50% phosphatidylserine vesicles and cardiolipin. These phospholipids were able to produce an apparent 3-fold enhancement of purified human protein C activation by human alpha-thrombin in the presence of purified human placenta thrombomodulin. In the absence of phospholipid, the anticoagulant fraction had no effect on thrombomodulin activity. The anticoagulant fraction could neutralize the enhancement of thrombomodulin activity by phospholipid in a dose-dependent manner. This study suggests that the neutralization of phospholipid might result in a reduced activation of protein C which could be responsible for the occurrence of thrombotic complications in a proportion of patients with lupus anticoagulants.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3018955

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  20 in total

Review 1.  Clinical trials for the antiphospholipid syndrome.

Authors:  J T Merrill
Journal:  Curr Rheumatol Rep       Date:  2000-06       Impact factor: 4.592

Review 2.  The antiphospholipid syndrome and atherosclerosis: clue to pathogenesis.

Authors:  Joan T Merrill
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 3.  Antiphospholipid syndrome: multiple mechanisms.

Authors:  C G Mackworth-Young
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 4.  Physiopathology of thrombosis induced by antiphospholipid antibodies.

Authors:  J M Zini
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 5.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

6.  Localization of the apoptosis-inducing activity of lupus anticoagulant in an annexin V-binding antibody subset.

Authors:  N Nakamura; T Ban; K Yamaji; Y Yoneda; Y Wada
Journal:  J Clin Invest       Date:  1998-05-01       Impact factor: 14.808

7.  Anticardiolipin antibodies do not seem to be associated with APC resistance in vivo or in vitro.

Authors:  D A Tsakiris; M L Yasikoff; F Wolf; G A Marbet
Journal:  Ann Hematol       Date:  1995-10       Impact factor: 3.673

8.  Role of beta 2-glycoprotein I and anti-phospholipid antibodies in activation of protein C in vitro.

Authors:  D M Keeling; A J Wilson; I J Mackie; D A Isenberg; S J Machin
Journal:  J Clin Pathol       Date:  1993-10       Impact factor: 3.411

9.  The anti-phospholipid antibody syndrome in a 77 year old man with digital gangrene.

Authors:  S W Roche; D C Niriella; A O'Mahoney; A C Cayley
Journal:  Postgrad Med J       Date:  1989-11       Impact factor: 2.401

10.  Inhibitory effects of anticardiolipin antibodies on lymphocyte proliferation and neutrophil phagocytosis.

Authors:  C L Yu; K H Sun; C Y Tsai; S R Wang
Journal:  Ann Rheum Dis       Date:  1991-12       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.